PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
January 27, 2019European Journal of Cancer736 citationsOpen Access

Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort

SSSigbjørn SmelandSBStefan BielackJWJeremy Whelan

Structured PICO

P
Population
>2000 patients with osteosarcoma registered to the EURAMOS-1 cohort
O
Outcome
Survival rates and prognostic factorshard clinical

Large-scale data from the EURAMOS-1 cohort confirms existing survival rates and prognostic factors in osteosarcoma.

Abstract

In conclusion, data from >2000 patients registered to EURAMOS-1 demonstrated survival rates in concordance with institution- or group-level osteosarcoma trials. Further efforts are required to drive improvements for patients who can be identified to be at higher risk of adverse outcome. This trial reaffirms known prognostic factors, and owing to the large numbers of patients registered, it sheds light on some additional factors to consider.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Smeland et al. (2019) studied this question.

synapsesocial.com/papers/69d898b1de3177251abeda8ahttps://doi.org/10.1016/j.ejca.2018.11.027
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Osteosarcoma incidence and survival rates from 1973 to 20042009 · 2,210 citations
  2. 2Osteogenic sarcoma with clinically detectable metastasis at initial presentation.1993 · 395 citations
  3. 3The evolving classification of soft tissue tumours: an update based on the new WHO classification2005 · 917 citations
  4. 4The evolving classification of soft tissue tumours – an update based on the new 2013 WHO classification2013 · 441 citations
  5. 5Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial2016 · 553 citations